The characteristics and treatment patterns of patients with Parkinson’s disease in the United States and United Kingdom: A retrospective cohort study


Autoři: Linda Kalilani aff001;  David Friesen aff002;  Nada Boudiaf aff002;  Mahnaz Asgharnejad aff001
Působiště autorů: UCB Pharma, Raleigh, North Carolina, United States of America aff001;  UCB Pharma, Slough, United Kingdom aff002
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225723

Souhrn

Objectives

The objective of the study was to describe treatment patterns in patients newly diagnosed with Parkinson’s disease (PD) in the United States (US) and the United Kingdom (UK).

Methods

This retrospective cohort study used the US IBM MarketScan database (2012–2017) and the UK Clinical Practice Research Datalink (CPRD) (2004–2015) database to describe treatment patterns in incident PD cases. Patients fulfilling the case definition of PD, ≥30 years, with a 2-year baseline period prior to the index date (date of PD diagnosis), and ≥90 days of follow-up were included in the study. Treatment was classified as monotherapy (one PD medication for ≥60 continuous days), polytherapy (at least two PD medications concurrently for ≥60 days), or untreated (no PD medication prescription). Treatment patterns described included type of medication, duration and outcome of treatment.

Results

There were 11,280 patients in IBM MarketScan and 7775 patients in CPRD who fulfilled the study criteria. The proportion of treated patients was 62.4% (US) and 78.6% (UK). The majority of patients were prescribed monotherapy as first-line treatment (US: 85.2%, UK: 68.5%). Levodopa was the most frequently prescribed first-line medication (US: 70.1%, UK: 29.0%). There were 57.9% in the US and 23.8% in the UK who remained on the first monotherapy treatment till the end of the study.

Conclusion

The study has highlighted the current treatment practices in the US and UK, and underscored differences in the two regions impacted by treatment policies and guidelines.

Klíčová slova:

Critical care and emergency medicine – Database and informatics methods – Diagnostic medicine – Drug therapy – Inpatients – Levodopa – Parkinson disease – Polytherapy drug treatment


Zdroje

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1: S1–S58. doi: 10.1007/s10654-011-9581-6 21626386

2. Xia R, Mao ZH. Progression of motor symptoms in Parkinson's disease. Neurosci Bull. 2012;28: 39–48. doi: 10.1007/s12264-012-1050-z 22233888

3. Hely MA, Reid WGJ, Adena MA, Halliday GA, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23: 837–844. doi: 10.1002/mds.21956 18307261

4. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8: 464–474. doi: 10.1016/S1474-4422(09)70068-7 19375664

5. Fayard C, Bonaventure A, Benatru I, Roze E, Dumurgier J, Moisan F, et al. Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France. Parkinsonism Relat Disord. 2011;17: 543–546. doi: 10.1016/j.parkreldis.2011.04.020 21612970

6. Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Yamamoto M, et al. Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. PLoS One. 2014;9: e99021. doi: 10.1371/journal.pone.0099021 24906013

7. Dahodwala N, Willis AW, Li P, Doshi JA. Prevalence and correlates of anti-Parkinson drug use in a nationally representative sample. Mov Disord Clin Pract. 2017;4: 335–341. doi: 10.1002/mdc3.12422 30363446

8. Crispo JA, Fortin Y, Thibault DP, Emons M, Bjerre LM, Kohen DE, et al. Trends in inpatient antiparkinson drug use in the USA, 2001–2012. Eur J Clin Pharmacol. 2015;71: 1011–1019. doi: 10.1007/s00228-015-1881-4 26081062

9. Liu WM, Wu RM, Chang CH, Lin JW, Liu YC, Lin CH. National trends of antiparkinsonism treatment in Taiwan: 2004–2011. Parkinsons Dis. 2016;2016: 1859321. doi: 10.1155/2016/1859321 26989558

10. Machado-Alba JE, Calvo-Torres LF, Gaviria-Mendoza A, Castrillón-Spitia JD. [Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015]. Biomedica. 2018;38: 417–426. doi: 10.7705/biomedica.v38i4.3781 30335247


Článek vyšel v časopise

PLOS One


2019 Číslo 11